GPX4 and nasopharyngeal carcinoma: To begin to test this hypothesis, we treated dermal fibroblasts from NPC patients and controls with Ras-selective Lethal 3 (RSL3), a ferroptosis inducer that inhibits GPx4 activity, thereby impairing antioxidant defenses against lipid peroxidation [20,21] (Figure 4a).